SYMBIOTEC Share Price Target 2050

CAGR-based price projection for Symbiotec Pharmalab Limited (SYMBIOTEC) targeting 2050, derived from official NSE exchange closing prices.

Bear Case (3.7% CAGR)
Rs 2,835
2050 Target
Base Case (9.1% CAGR)
Rs 9,768
2050 Target
Bull Case (24.8% CAGR)
Rs 246,116
2050 Target

Current Market Snapshot

CMP: Rs 1,198.00
52W High: Rs 1,198.00
52W Low: Rs 1,003.35
1Y CAGR: 19.1%
3Y CAGR: 9.1%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 1,242 Rs 1,307 Rs 1,496
2028 Rs 1,287 Rs 1,427 Rs 1,867
2029 Rs 1,334 Rs 1,557 Rs 2,331
2030 Rs 1,383 Rs 1,700 Rs 2,910
2031 Rs 1,434 Rs 1,855 Rs 3,633
2032 Rs 1,486 Rs 2,024 Rs 4,536
2033 Rs 1,540 Rs 2,209 Rs 5,662
2034 Rs 1,597 Rs 2,411 Rs 7,069
2035 Rs 1,655 Rs 2,632 Rs 8,825
2036 Rs 1,715 Rs 2,872 Rs 11,017
2037 Rs 1,778 Rs 3,134 Rs 13,754
2038 Rs 1,843 Rs 3,421 Rs 17,171
2039 Rs 1,910 Rs 3,733 Rs 21,437
2040 Rs 1,980 Rs 4,075 Rs 26,762
2041 Rs 2,053 Rs 4,447 Rs 33,411
2042 Rs 2,128 Rs 4,853 Rs 41,711
2043 Rs 2,205 Rs 5,297 Rs 52,072
2044 Rs 2,286 Rs 5,781 Rs 65,008
2045 Rs 2,370 Rs 6,309 Rs 81,158
2046 Rs 2,456 Rs 6,885 Rs 101,320
2047 Rs 2,546 Rs 7,514 Rs 126,490
2048 Rs 2,639 Rs 8,201 Rs 157,913
2049 Rs 2,735 Rs 8,950 Rs 197,142
2050 Rs 2,835 Rs 9,768 Rs 246,116

Other SYMBIOTEC Price Targets

2025 2026 2027 2028 2030 2035 2040

Frequently Asked Questions

What is the SYMBIOTEC share price target for 2050?

Based on historical growth analysis, the SYMBIOTEC share price target for 2050 ranges from Rs 2,835 (conservative) to Rs 9,768 (base case) to Rs 246,116 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of SYMBIOTEC?

The current market price of SYMBIOTEC (Symbiotec Pharmalab Limited) is Rs 1,198.00. The 52-week high is Rs 1,198.00 and 52-week low is Rs 1,003.35.

Is SYMBIOTEC a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for SYMBIOTEC price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 3.7% CAGR), Base (9.1% CAGR), and Bull (optimistic at 24.8% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.